Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent are helping small- to mid-sized biotechs stay nimble.
Onyx @ Union Square: Colleen Cutcliffe, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
"It's like Duolingo for sewing" - how Della Yellow is ushering in the age of circular fashion
A digital community for clothing repairs has high hopes to upskill consumers worldwide and trigger an upcycle revolution.
How Piramal Pharma plans to become a multi-billion dollar business
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
We all want our hospital records in one place. Is Novellia the app to do it?
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx Studio Sessions: Fabian Gerlinghaus, Cellares
Can this man bring down the cost of some of the most expensive and hope-inspiring new therapies on the market?
Backed by AstraZeneca, this company is helping radioligand cancer therapies hit the shelves
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
This biotech is targeting the 'immortality switch' to fight blood cancers
Harnessing Nobel Prize-winning insights on telomeres, Geron’s CEO Dr. John A. Scarlett is taking on some of hematology’s toughest challenges—and winning FDA backing in the process.
NVIDIA’s Biggest Bet Yet: How Recursion Is Powering a New Era of AI-Driven Drug Discovery
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases
A Grammy-winning CEO is taking gene therapy to new heights.
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Mayo Clinic-backed, Halle Berry-approved: Pendulum’s Dr. Colleen Cutcliffe is tackling type 2 diabetes before it even starts.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
From paper to pancreas: how Aspect Biosystems is leading a bioprinting revolution
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
Could a single pill crack the code of treating Alzheimer's disease?
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.